Nasal test for human prion disease developed
News Aug 07, 2014
A nasal brush test can rapidly and accurately diagnose Creutzfeldt-Jakob disease (CJD), an incurable and ultimately fatal neurodegenerative disorder, according to a study by National Institutes of Health (NIH) scientists and their Italian colleagues.
Up to now, a definitive CJD diagnosis requires testing brain tissue obtained after death or by biopsy in living patients. The study describing the less invasive nasal test appears in the Aug. 7 issue of the New England Journal of Medicine.
CJD is a prion disease. These diseases originate when, for reasons not fully understood, normally harmless prion protein molecules become abnormal and gather in clusters. Prion diseases affect animals and people. Human prion diseases include variant, familial and sporadic CJD. The most common form, sporadic CJD, affects an estimated 1 in one million people annually worldwide. Other prion diseases include scrapie in sheep; chronic wasting disease in deer, elk and moose; and bovine spongiform encephalopathy (BSE), or mad cow disease, in cattle. Scientists have associated the accumulation of these clusters with tissue damage that leaves sponge-like holes in the brain.
"This exciting advance, the culmination of decades of studies on prion diseases, markedly improves on available diagnostic tests for CJD that are less reliable, more difficult for patients to tolerate, and require more time to obtain results," said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), a component of NIH. "With additional validation, this test has potential for use in clinical and agricultural settings."
An easy-to-use diagnostic test would let doctors clearly differentiate prion diseases from other brain diseases, according to Byron Caughey, Ph.D., the lead NIAID scientist involved in the study. Although specific CJD treatments are not available, prospects for their development and effectiveness could be enhanced by early and accurate diagnoses. Further, a test that identifies people with various forms of prion diseases could help to prevent the spread of prion diseases among and between species. For instance, it is known that human prion diseases can be transmitted via medical procedures such as blood transfusions, transplants and the contamination of surgical instruments. People also have contracted variant CJD after exposure to BSE-infected cattle.
The NIAID study involved 31 nasal samples from patients with CJD and 43 nasal samples from patients who had other neurologic diseases or no neurologic disease at all. These samples were collected primarily by Gianluigi Zanusso, M.D., Ph.D., and colleagues at the University of Verona in Italy, who developed the technique of brushing the inside of the nose to collect olfactory neurons connected to the brain. Testing in Dr. Caughey's lab in Montana then correctly identified 30 of the 31 CJD patients (97 percent sensitivity) and correctly showed negative results for all 43 of the non-CJD patients (100 percent specificity). By comparison, tests using cerebral spinal fluid -- currently used to detect sporadic CJD -- were 77 percent sensitive and 100 percent specific, and the results took twice as long to obtain.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
Christina D. Orrú, Matilde Bongianni, Giovanni Tonoli, Sergio Ferrari, Andrew G. Hughson, Bradley R. Groveman, Michele Fiorini, Maurizio Pocchiari, Salvatore Monaco, Byron Caughey, Gianluigi Zanusso. A Test for Creutzfeldt–Jakob Disease Using Nasal Brushings. New England Journal of Medicine, Published August 7 2014. doi: 10.1056/NEJMoa1315200
Expect a shot to hurt and it probably will, even if the needle poke isn’t really so painful. Brace for a second shot and you’ll likely flinch again, even though—second time around—you should know better. That’s the takeaway of a new brain imaging study which found that expectations about pain intensity can become self-fulfilling prophecies.
Intensive behavioral therapy (IBT), which provides diet and physical activity counseling, could help adults with obesity achieve meaningful weight loss in six to 12 months. The trial showed that patients who received IBT lost an average of 6.1 percent of their initial body weight at one year.READ MORE